VIEW
View, Inc. Class A Common Stock
stock NASDAQ

Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/1971622166090366996)
>BOWMAN SAYS SHIFT IS PROPER AS INFLATION IS EXPECTED TO DROP SIGNIFICANTLY NEXT YEAR || INFLATION LIKELY TO RETURN TO 2% AFTER ONE\-TIME TARIFF ADJUSTMENT
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/1971622213901230318)
>BOWMAN SAYS IT IS PROPER TO REVIEW THE ONE\-TIME EFFECTS OF TARIFFS AND CLAIMS THE ECONOMY MIGHT BE SEEING A LONG\-LASTING PRODUCTIVITY BOOST DUE TO NEW TECHNOLOGY
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/1971622284973822116)
>BOWMAN CRITICIZES RIGID DATA\-DRIVEN APPROACH, WARNS IT KEEPS ECONOMY BEHIND AND RECOMMENDS FED TO ADOPT FORWARD\-LOOKING STRATEGY
Tweet Mirror:[FirstSquawk](https://twitter.com/FirstSquawk/status/1971622335414472944)
>BOWMAN CRITICIZES THE FIXED AND DOGMATIC FOCUS ON RECENT DATA, CLAIMING IT RESULTS IN A BACKWARD\-LOOKING VIEW OF THE ECONOMY AND KEEPS US BEHIND\. HE SUGGESTS THE FEDERAL RESERVE SHOULD SWITCH FROM EMPHASIZING CURRENT DATA TO ADOPTING A PROACTIVE, FORWARD\-LOOKING APPROACH\.

*First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer Center*
*Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of Vermont Cancer Center as Participating Clinical Sites*
*The PanTheR Study is Gathering Expanded Safety and Performance Data of the FDA-Cleared RenovoCath**^(®)* *Device and its Associated Survival Outcomes in Patients Diagnosed with Solid Tumors* 
https://preview.redd.it/uuf0d3odbcrf1.png?width=300&format=png&auto=webp&s=d3e6d031243372333bc84275654b779ce77439b9
MOUNTAIN VIEW, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- [**RenovoRx, Inc**](https://www.globenewswire.com/Tracker?data=_YCtv3Fofm_2dSZCiRQMMW9C4kPjIqLsXOsvWmoV0NwRVEzqi6-3EOjNV_mHrz_Oj-Zf5HdBZQvQWIJgtZm2KA==)**. (“RenovoRx” or the “Company”) (Nasdaq: RNXT)**, a life sciences company developing innovative targeted oncology therapies and commercializing **RenovoCath**, a patented, FDA-cleared drug-delivery device, today announced that the first registry-eligible patient procedure in its **PanTheR Post-Marketing Registry Study** (NCT06805461) has been successfully completed at the University of Vermont Cancer Center.
RenovoRx also announced that Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center have joined the University of Vermont Cancer Center as participating clinical sites in the PanTheR registry study. The Principal Investigators at the first three PanTheR clinical sites include Dr. Ripal Gandhi, interventional radiologist at Baptist Health Miami Cancer Institute, Dr. Paula Novelli, interventional radiologist at University of Pittsburgh Medical Center, and Dr. Conor O’Neill, surgical oncologist at the University of Vermont Cancer Center. The study has commenced at the University of Vermont Cancer Center with Dr. O’Neill’s team, with the additional two sites expected to initiate patient procedures soon.
These milestones underscore the important role of the PanTheR study in assessing the safety and effectiveness of RenovoCath in real-world settings. RenovoRx plans to issue additional updates as patient enrollment accelerates and cancer treatments delivered with RenovoCath expand across a broader range of solid tumors and participating sites.
“We are pleased to be the first site to initiate cancer treatment delivery by RenovoCath in the important PanTheR registry study,” said Dr. Conor O’Neill of the University of Vermont Cancer Center. “This study provides a crucial opportunity to evaluate how RenovoCath can improve drug-delivery in patients diagnosed with solid tumors, while potentially, and importantly, improving survival and quality of life outcomes. By contributing to this registry study, we aim to generate meaningful real-world data that can guide future treatment decisions for patients with difficult-to-treat cancers.”
The PanTheR study reinforces RenovoRx’s commitment to innovation and the potential of RenovoCath to improve outcomes for patients diagnosed with solid tumors. By capturing real-world data and evaluating long-term safety and survival outcomes, PanTheR will enhance safety protocols and help shape future clinical trials and targeted drug-delivery applications for RenovoCath.
**About the PanTheR Post-Marketing Registry Study**
A post-marketing registry study is a clinical study that involves collecting data on the long-term use and performance of a medical device, such as RenovoCath, after it has been cleared for market by the FDA. PanTheR is a multi-center, post-marketing observational registry study designed to evaluate the long-term safety of and survival outcomes for patients diagnosed with solid tumors who are treated using RenovoCath for targeted drug-delivery. PanTheR will capture real-world data on the utilization of RenovoCath and generate additional safety information across a broader range of solid tumors. This data may be used to inform future clinical trial designs. Cancer centers participating in the registry study will purchase RenovoCath devices from RenovoRx for use in the study.
**About RenovoCath**
Based on its FDA clearance, RenovoCath^(®) is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: [IFU-10004-Rev.-G-Universal-IFU.pdf](https://www.globenewswire.com/Tracker?data=59agVLteMs5_UxASyQSb6bqOiOUTGlA8QQI38BLGv4NtQgXHBqihWclNXSH0u1zX6jEqXva414IavW2t4DA6UgwIcZD2StbnrWCO6O2IUmzlNdvwXqi6ansFu9pW8hG0iViPP0EgAymcuyxflIpqyQHwPo346S0oS3ytTk_0L_RjadcUfiLbbJQ9tDAS8boIieQklGoraTE1gxfqg9ij5bnxg7hjgUAJiB_rCzsqplj_maAt1dzxCx_o4SguCYXSeSu3q50AO5oKj8ARD1w8kqTJvth3HbtW1SE4VvMy_Wq0qB9TIcJtSQ_-rlV_d744pByuNG-r00zQBNqZYATZepNWxvMUNzCmtr8hB6qLfhKLfk-2cF9UkH51l91NGfn2NhAIhKEMp2vfdd-sbW-BipsJw0qKWY05kwuPX7P44UmGzl_GJloy_xJUyGNDNbDruXKGJtLoJ8wnxU1a_yCyYL5hpcpXB-7eqhdh_xFYMm8=).
**About RenovoRx, Inc.**
**RenovoRx, Inc. (Nasdaq: RNXT)** is a life sciences company developing innovative targeted oncology therapies and commercializing **RenovoCath****^(®)****,** a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented **Trans-Arterial Micro-Perfusion (TAMP™)** therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted drug-delivery offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
In addition to the RenovoCath device, RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
The combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.
RenovoRx is also actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, several of these customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.
For more information, visit [www.renovorx.com](https://www.globenewswire.com/Tracker?data=nslr35gCnUaYe1CE6bLGf0TwGcU-myvtiloE3UBhFQqvWxh4SYyMNuX3VT4YFz8PiLNCCAd9mRmNGjOReFgDCLIcFDTmeqtAAZop2NzQmnVuhRZZKT3dkO257kkxrocNt_prLOGI6jJdm9Gfl1laeb2c3bhDSXEscXaNdQg-6lkhHdoMo7IRXJrnctLArSZCoqQrr_ptcJ_lA8e_7xFgzc6UF579n15xvr7hl9AemVIBkGJhXaGajF_GAdKsDqZO0xpo4eZbnpHya_gniTpmQW0J7TgO2ST0ppv440B-fJI6Fx5q8AbXwutFNMRJkW1xVGbeY9qtg0dDFEESmeXiiTeG__KL1sZ6fV0nrLw2Kv0BrNn_yGeagghnVEMViAAd). Follow RenovoRx on [Facebook](https://www.globenewswire.com/Tracker?data=1WyaeIiN200_iPaDbzQPLsPR0pny9ttx-qOnzxad2teCzYkKL6ciV3z3eyBiCtDL3on4VZSdqnDEiRBtyjNNhE6ppW2lZdT92jNb9Hk2qkn2MNhrbj8D4yxiH-b8MyA5p9m07HwUO2cXcPy-3fJ4FBA731ekg7ygHuU7ALgP5lTHwlAo7bekVr11x2FLDvu30pQDaKm9_FTEkBDHZMOIdWVCEPFLE_BdQiCWTnp-uzDRRVrkMpa8cg6APNEeW90F51MPkpmZEu79Gf2axiX58N9YAxE4HmDT78sWC2euSLi0T7CAsPT8NxdFM3D-BJzvZ_kjMxViEZIRguIXov68NYD_QzQY_Eaat2PUck1DOLkVq4gfXx105nLStFZZFmIe), [LinkedIn](https://www.globenewswire.com/Tracker?data=xFaJ7f6P2KIh5z5W3vlNefbC2Ot9VVNgHMHDwHKJmMIeZHGlOm5BWtFNCmyRuNxdONFKCNrLAhnWpSceqoTH8gNHe8_8wXGiy95NZqmN8EGLE2_VJc1sjNg3r00lSkcrlcwFlYQkWfMIamBg87RLGXfHvT-LNQj_10RhspNJFVEYowt7SXi_F_yeeBX1XfDDD6Y80uWt7tsf1ndPVb4vBYrmoIApPwG2F4V4rjb_vGJJK73eDV9qjBpFoIb6pyN5JpzhYN1RzkEVCJb41-6pfQ_1kvTt15uNk_IS7N3I6BQyDJFHWGQsxRPRVh7LRbxCpKAZOfZgKHYBOTTK2j9n2rntbIHi3HnZlA8TXN8FcHsmJk0dtqWu2Vkw-Th-Kari8HsD89MC36P1SHoPjthDxxF7H2vNxHTPQ-aW0N5ot3U=), and [X](https://www.globenewswire.com/Tracker?data=G7X-XSTntr6hOAtZzwe595EmcNSvzyPauSxtr36C9EylKalKjfFOmKTG8aCpsfL6HRHyGsXW4VJT44gZEPm2qcGP4Dn--mA8S7aW5QJhg0a6WnO2bhhwWQkOWJWWoXSAnb6khTkRVu0xZL92SHjMWeBpWLfbVKsFKMxo3DxaymIJlQX3o1Y8ov_6hmqe7Rngzp16Y30VbRgHCPiAcPOIQQ5lxc42iz8BJObaz3BqY-Mj_Wh4c6URM8BSsyelv4rON-slqp4HJFmkyPjMSXbG_O0PWVHDk4kyc7sBCHY174J_UMnaDwXdo6wpu-PsQyR0xnoowFkgFqbykxs2A3DiIiv8ezpDOhh12dlrbT7OZAg=).